EBMT 2020 | NK CAR-based therapies & future perspectives

Name: NK CAR-based therapies & future perspectives
Uploaded: 2020-08-31T00:00:00Z
Duration: 2 min 6 s
Description: Tobias Bexte, cand.med., University Hospital Frankfurt, Goethe University, Frankfurt, Germany, gives an outlook on natural killer (NK) chimeric antigen receptor (CAR)-based therapies and what the future may look like. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Tobias Bexte • 31 Aug 2020

EBMT 2020

Acute Lymphoblastic Leukemia Leukemia CAR-T NK-Cell Therapy

Tobias Bexte, cand.med., University Hospital Frankfurt, Goethe University, Frankfurt, Germany, gives an outlook on natural killer (NK) chimeric antigen receptor (CAR)-based therapies and what the future may look like. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).